Background Conventional pharmacological therapies for the treatment of juvenile idiopathic
arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which …

Methotrexate (MTX) is a derivative of folic acid (folate) and commonly used as an anchor
drug for the treatment of rheumatoid arthritis (RA). The pharmacokinetics (PK) and …

Introduction Interindividual differences in drug response are a frequent clinical challenge
partly due to variation in pharmacokinetics. ATP-binding cassette (ABC) transporters are …

Objective The objective was to predict insufficient response to 3 months methotrexate (MTX)
in DMARD naïve rheumatoid arthritis patients. Methods A Multivariable logistic regression …

Background and Aims: Accurately predicting the response to methotrexate (MTX) in juvenile
idiopathic arthritis (JIA) patients before administration is the key point to improve the …

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of
childhood. The outcome in patients with JIA has markedly improved with the advent of …

Introduction: For the elimination of environmental chemicals and metabolic waste products,
the body is equipped with a range of broad specificity transporters that are present in …

Philip J. Hashkes, MD, MSc1, Mara L. Becker, MD, MSCE2, David A. Cabral, MBBS3,
Ronald M. Laxer, MD, FRCPC4, Amy S. Paller, MD, MS5, C. Egla Rabinovich, MD, MPH6 …

Rheumatoid arthritis (RA) is a complex, systemic autoimmune disease characterized by
chronic inflammation of multiple peripheral joints, which leads to serious destruction of …

Understanding the genetic risk of JIA, a relatively rare chronic disease, is a challenging task,
but recent research in this field has shown great advances. This review summarizes the …